How would you treat refractory diarrhea in a patient with low grade serous ovarian cancer treated with Trametinib?

Trametinib is known to cause significant diarrhea with 43% of patients affected with grade 1 or 2 diarrhea in phase II/III trials¹. The recently released abstract for NRG-GOG 0281 reported on progression-free and overall survival, as well as toxicities related to use of Trametinib versus standard of...